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Context: Adolescents with polycystic ovary syndrome (PCOS) have increased incidence of 
cardiometabolic risk factors including dyslipidemia. Atherogenic apolipoprotein (apo) B-lipoprotein 
remnants are associated with increased cardiovascular disease (CVD) risk.
Objective:  The aim of this study was to determine the concentrations of fasting plasma apoB-
lipoprotein remnants, apoB48 and apoB100, and their association with cardiometabolic risk factors 
and androgen indices in adolescent girls with and without PCOS.
Design, setting and participants:  Participants (n  =  184) aged 17  years were recruited in the 
Menstruation in Teenagers Study from the Western Australian Pregnancy Cohort (Raine) Study.
The main outcome measures:  Fasting plasma apo-B48 and -B100 lipoprotein remnant 
concentrations in adolescent girls with and without PCOS.
Results: Fasting plasma apoB48-lipoprotein remnants but not apoB100-lipoprotein remnants were 
elevated in adolescent girls with increased cardiometabolic risk compared with those with lower 
cardiometabolic risk (13.91 ± 5.06 vs 12.09 ± 4.47 µg/mL, P < .01). ApoB48-lipoprotein remnants were 
positively correlated with fasting plasma triglycerides (b = .43, P < .0001). The prevalence of increased 
cardiometabolic risk factors was 2-fold higher in those diagnosed with PCOS (35.3%) than in those 
without PCOS (16.3%).
Conclusion: Adolescents with PCOS have a 2-fold higher incidence of cardiometabolic risk factors 
than those without PCOS. Fasting apoB48-lipoprotein remnants are elevated in adolescent girls with 
a high prevalence of cardiometabolic risk factors.
© Endocrine Society 2020.
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Polycystic ovary syndrome (PCOS) is a metabolic endocrine disorder that is highly asso-
ciated with the metabolic syndrome (MetS) and cardiometabolic risk factors, including 
obesity, dyslipidemia, and insulin resistance [1]. Women with PCOS are reported to have 
increased incidence of type-2 diabetes and premature cardiovascular disease (CVD) [1-4]. 
In adolescents and young women (17-35  years) with PCOS and the MetS, increased in-
cidence of early subclinical atherosclerotic CVD (ACVD), such as carotid intimal medial 
thickening (cIMT), has been reported [5-12]. Early development of ACVD may predispose 
women with PCOS to increased morbidity and mortality associated with ischemic CVD 
events [5-12]. A primary risk factor in the development of atherosclerosis and CVD is ath-
erogenic dyslipidemia, and adolescents with features of the MetS and PCOS have been re-
ported to have a higher incidence of dyslipidemia [10, 13-19].
Atherogenic dyslipidemia includes increased fasting plasma triglycerides (TGs), total 
apoB, and decreased high-density lipoprotein cholesterol (HDL-C) concentrations [20]. 
Evidence from the Copenhagen City Heart Study and ACCORD lipid study has also shown 
that elevated nonfasting plasma apoB-remnant lipoproteins are causally associated with 
cardiovascular ischemic events [21, 22]. These studies reveal the importance of plasma 
apoB-lipoprotein remnants in predicting CVD risk. ApoB-lipoprotein remnants are de-
rived from both the intestine (chylomicrons and chylomicron remnants containing apoB48) 
and the liver (very low-density lipoprotein, and low-density lipoprotein [LDL] remnants 
containing apoB100) [22, 23]. Few studies report quantitation of both of these atherogenic 
apoB-lipoprotein remnants. Impaired apoB48-CM metabolism in the fasted and nonfasted 
state has been observed in normolipidemic conditions and in those with increased incidence 
of CVD, including obesity, MetS, and diabetes [22, 24].
Plasma testosterone (T) concentrations have been positively associated with plasma TG 
and total apoB, and an adverse lipid profile is highly correlated with androgens in adolescents 
and young women with PCOS [14, 25, 26]. We have shown adolescent girls with the MetS 
have elevated fasting and nonfasting plasma TG and apoB48 compared with healthy weight 
controls, and this is further exacerbated in those diagnosed with PCOS [27]. We have also 
shown fasting and nonfasting plasma TG and apoB48 are positively correlated with an-
drogen indices, including free androgen index (FAI) and free T [27]. Whether these results 
are observed in a large population cohort of adolescent girls with PCOS remains unknown. 
The aim of this study was to determine the fasting plasma apoB48 and apoB100-lipoprotein 
remnant concentrations in adolescent girls aged 17 years with and without PCOS from the 
Raine Cohort Study, and the association with cardiometabolic risk factors and androgen in-
dices. We hypothesized that apoB-lipoprotein remnants would be positively correlated with 
the prevalence of cardiometabolic risk factors and androgen indices in adolescents with and 
without PCOS.
1. Material and Methods
A.  Study Population
The Western Australian Pregnancy Cohort (Raine) Study (http://www.rainestudy.org.au) 
was designed to measure the relationship between early life events and subsequent health 
and behavior [28]. The Raine study is a longitudinal pregnancy cohort study of 2868 chil-
dren born between 1989 and 1992 in Perth, Western Australia. Recruitment and follow-up 
of the cohort has been previously described in detail [28]. The cohort has undergone serial 
cross-sectional assessments since birth and in the current study assessments were performed 
when the cohort reached the age of 17 years, and is representative of the Western Australia 
adolescent population [29, 30]. The study was conducted with institutional approval from 
the Human Research Ethics Committee of King Edward Memorial Hospital and Princess 
Margaret Hospital for Children. The adolescent and the primary caregiver provided written 
assent and consent, respectively. Adolescent girls (n = 244) from the Raine Study volunteered 
in the assessment of reproductive function in the Menstruation in Teenagers Study, and 
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the participants were at least 2 years post menarche (2.6 ± 0.3-7.0 years), as previously 
described [17]. The timing or onset of menarche was prospectively determined from re-
sponse to serial questionnaires [17]. The 2-year follow-up assessment at age, approximately 
16 to 17 years, in this cohort has been previously published, including methodology for an-
thropometric and blood pressure measurements [31-33]. Participants were excluded from 
the current analyses if they did not have complete biochemical and anthropometric data 
sets, and at the time of the 2-year follow-up no participants were diagnosed with diabetes. 
In the current study, of the 244 participants in the Menstruation in Teenagers Study, at the 
2-year follow-up, 184 participants were identified that had both a fasting plasma sample 
and a PCOS diagnostic screening available, and were aged 17.04 ± 0.23 years (Table 1).
B.  PCOS Diagnosis and Androgen Status Assessment
The PCOS-National Institute of Health (NIH) and PCOS-Androgen Excess and Polycystic 
Ovary Syndrome Society (AEPCOSS) criteria were used to define PCOS when the study 
was conducted, and the incidence of PCOS was compared between the 2 criteria [17]. 
The latter AEPCOSS was considered more applicable for a rigorous diagnosis of PCOS in 
adolescents [34]. The PCOS-NIH criteria were met if menstrual cycles were oligo-ovulatory 
or anovulatory together with either clinical or biochemical hyperandrogenemia [34]. The 
AEPCOS adolescent criteria for PCOS diagnosis was based on evidence of ovarian dys-
function, either using clinical evidence of oligo/anovulation, and either biochemical or clin-
ical evidence of hyperandrogenism, and persistent oligomenorrhea for 2 to 3 years beyond 
menarche [34]. Polycystic ovary morphology was assessed by transabdominal ultrasound 
evaluation of ovarian size and morphology performed by 1 of 2 experienced gynecologic 
ultrasonographers. Polycystic ovary morphology was defined according to standard inter-
national criteria at the time of data collection (NIH/AEPCOSS), that is, 1 or more ovaries 
>10 cm3 or R12 follicles between 2 and 9 mm in diameter [34]. The presence of ovulation was 
assessed by initially screening with a prospective menstrual diary, collected over 3 months, 
to establish menstrual regularity. Irregular cycles were defined as those <25 or >35 days 
in duration or where the cycle length varied from month to month by >4  days [17, 34]. 
Other causes of oligo-ovulation or anovulation were excluded by measuring thyroid-stim-
ulating hormone and prolactin concentrations. Clinical hyperandrogenism was assessed 
by the presence of hirsutism, with use of the Ferriman–Gallwey scoring system [34]. 
Biochemical hyperandrogenism was defined as concentrations in the upper 25th centile 
of free T (calculated free T), which was >24.45 pmol/L (conversion factor to conventional 
units divide by 0.347 for pm/dL) for this data set. Sex hormone-binding globulin (SHBG) 
was measured in duplicate by immunoassay with use of a noncompetitive liquid phase 
immunoradiometric assay (SHBG-IRMA kit; Orion Diagnostica, Espoo, Finland): intra-
assay and interassay coefficients of variation were <5% to 8.6% and 15.4%, respectively. 
Total T was measured in duplicate by radioimmunoassay (Repromed Laboratory, Adelaide, 
Australia) (lower limit of sensitivity 0.347  nmol/L; normal female range 0.5-2.5  nmol/L; 
conversion factor to conventional units divide by 0.347 for nanograms per deciliter). The 
intra-assay and interassay coefficients of variation are 6% and 15% at the 1 nmol/L concen-
tration, respectively. Calculated free T was calculated from the measured total T and SHBG 
concentrations, concentrations, and FAI was calculated as total T/SHBG ×100 using with 
use of standardized methods [34] (http://www.issam.ch/freetesto.htm).
C.  Biochemical Analysis
Venous blood samples were obtained following an overnight fast (12 hours) and plasma pre-
pared following centrifugation of whole blood at 3000 rpm, and aliquots of samples stored 
–80°C [17, 32]. Standard plasma biochemistry analyses for the cohort were performed 
including, total cholesterol (TC), LDL-C, HDL-C, TGs, insulin, and glucose) in duplicate 
with a coefficient of variation of <5% intra-assay, and in multiple runs with a coefficient 
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of variation of <5% interassay for all assays, as previously described using accredited 
PathWest Laboratory at the Royal Perth Hospital [17]. LDL-C was calculated using the 
Friedewald formula [35]. Non-HDL-C cholesterol was calculated as TC (mmol/L) – HDL-C 
(mmol/L). The homeostasis model assessment index of insulin resistance (HOMA-IR) was 
calculated as insulin (µU/mL) × glucose (mmol/L)/22.5 [36].
D. Quantification of ApoB-lipoproteins
ApoB48 and ApoB100 lipoprotein remnants were quantified using a Western blot method, 
as previously established in our laboratory [27, 37]. ApoB analyses was performed on an 
aliquot of plasma previously stored at –80°C and thawed for this analyses once. Briefly, 
total plasma (2 µL [1:100]) loaded in sample buffer) proteins were separated on a 3% to 
8% NUPAGE Tris-acetate polyacrylamide gel and then transferred onto a polyvinylidene 
difluoride membrane. Membranes were incubated with a primary polyclonal antibody spe-
cific for ApoB (RRID:AB_92217) [38] and a secondary antibody tagged with horseradish 
peroxidase (RRID:AB_628490) [39]. ApoB48 and B100 bands were visualized by enhanced 
chemiluminescence and quantified using linear densitometric comparison (Image J) with a 
known mass of purified human ApoB48 and ApoB100 standard, as shown in Fig. 1 [27, 37].
E.  Cardiometabolic Cluster Analyses
The MetS definition in adults is based on cutoffs for metabolic biomarkers in adults and 
cannot be applied for use in adolescents. Therefore a 2-step cluster analysis algorithm tech-
nique for use in children and adolescents was originally developed to define those individuals 
with high and low cardiometabolic risk [40]. The cluster analyses uses the parameters waist 
circumference, fasting plasma TGs, LDL-C, HDL-C, glucose and insulin, and blood pres-
sure. The cluster analyses is an effective tool to use in defining groups based on variables 
that have strong evidence of clustering, such as obesity, hypertension, dyslipidemia, and 
insulin resistance. The cardiometabolic cluster has been used previously to define high 
and low cardiometabolic risk in adolescents in the Raine cohort, including those with and 
without PCOS, and in nonalcoholic fatty liver disease [17, 31, 32, 41].
F.  Statistical Analysis
Assumptions of normality, linearity, limited multi- and collinearity, and homoscedasticity 
were applied for continuous variables, and variables that did not assume a normal dis-
tribution of residuals (assessed by Q-Q plot) were log transformed. Categorical data 
were summarized with the use of frequency distributions. Univariate group comparisons 
were conducted with t-tests for continuous outcomes and chi-square tests for categorical 
outcomes. Select multiple linear regression models were used to further examine the rela-
tionship between primary lipid and apoB-lipoproteins and predictor variables of interest 
including, body mass index (BMI), and insulin and androgen indices. The level of statistical 
significance was set at P < .05. All statistical and graphical analyses were performed using 
Stata/IC 13.1 software (StataCorp LP).
Figure 1. Plasma ApoB quantification.
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2.  Results
A.  Metabolic and Biochemical Parameters
Metabolic and biochemical parameters in all adolescent girls and those diagnosed with 
PCOS according to NIH and AEPCOS Society criteria are shown in Table 1. PCOS diag-
nosis was confirmed in 18% and 9.2% of individuals based on NIH and AEPCOS criteria, 
respectively. BMI was significantly elevated by 3-4 kg/m2 in PCOS compared with the non-
PCOS group. Waist circumference was approximately 8-9 cm (9-12%) higher in individuals 
with PCOS, but not different between the PCOS-NIH or PCOS- AEPCOS groups. Serum 
total T, free T, and FAI were approximately 2-fold higher (P < .0001) in the PCOS groups 
than in non-PCOS, and there was no difference between PCOS-NIH or PCOS-AEPCOS 
groups. Serum SHBG was significantly lower by approximately 40% in PCOS than in non-
PCOS groups. Fasting plasma insulin concentration was >45% higher in those with PCOS 
using both NIH and AEPCOS diagnostic criteria. Consistently, HOMA-IR was 2.5- and 
2-fold higher in those with PCOS-NIH and PCOS-AEPCOS, respectively, compared with 
non-PCOS. The high-risk metabolic cluster was associated with a 2-fold higher incidence 
of PCOS, consistent with our previous reports in this cohort [17], and consistent with other 
reports in adolescents with PCOS [10, 17, 42, 43].
B.  Plasma Lipids and ApoB-lipoproteins
No significant difference was observed in fasting plasma lipids (TGs, LDL-C, HDL-C) or 
apoB-lipoprotein remnants (apoB48 and apoB100) in individuals with or without PCOS. 
Linear regression analyses investigated the relationship between fasting plasma apoB-
lipoprotein remnants with cardiometabolic risk factors independent of PCOS status 
(Table 2). Fasting apoB48 remnants were positively associated with plasma TGs (b = .43, 
P <  .0001), consistent with our previous findings in obese adolescents with and without 
PCOS [27]. ApoB48-lipoprotein remnants were inversely associated with fasting plasma 
HDL-C (b = –.10, P = .015). There was a positive association between apoB48 lipoprotein 
remnants and the high-risk metabolic cluster (b =  .152, P =  .032), predominately due to 
the strong correlation between plasma apoB48 remnants and plasma TGs. Individuals in 
the high-risk metabolic risk cluster had 1.82 µg/mL or approximately 15% higher apoB48-
lipoprotein remnant concentration than in those in the low-risk cluster. ApoB-100 lipopro-
tein remnants were significantly and positively correlated with TGs, TC, and LDL-C, but 
not with the high-risk metabolic cluster (Table 2).
Regression analyses of apoB100 and apoB48 with free T, total T, FAI, SHBG and DHEAS 
showed that fasting plasma apoB100 and apoB48-lipoprotein remnants were not associated 
with biomarkers of androgen status in adolescent girls (Table 2).
3.  Discussion
PCOS is associated with a higher incidence of cardiometabolic risk factors and a 2-fold 
higher incidence of ischemic CVD events later in life [1, 3, 44]. Early subclinical ACVD, 
including increased cIMT and endothelial dysfunction, and a higher incidence of the MetS 
and dyslipidemia have been observed in adolescents with PCOS [8, 10, 15, 17, 18]. However, 
limited data are available for atherogenic cholesterol dense apoB-lipoprotein remnants in 
adolescents with and without PCOS. Elevated concentrations of apoB-lipoprotein remnants 
are an early subclinical biomarker of CVD risk, and are causally associated with the devel-
opment of atherosclerosis and increased incidence of end-stage ischemic CVD events [22, 24, 
37, 45]. This is the first study to report apoB-lipoprotein remnant concentrations, apoB48 and 
apoB100, in a population-based cohort of adolescent girls with and without PCOS. We have 
shown that apoB48-lipoprotein remnants are elevated in adolescent girls with a high prev-
alence of cardiometabolic risk factors, including obesity, elevated plasma triglycerides, and 
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HOMA-IR. Adolescents with PCOS had a 2-fold higher prevalence of cardiometabolic risk 
factors than those without PCOS. Therefore in adolescents with increased cardiometabolic 
risk factors with or without PCOS, an increase in apoB48 remnants may predispose these 
individuals to early development of CVD [21, 24, 46].
Consistent with previous findings, we have shown both ApoB48 and apoB100 lipoprotein 
remnants are highly correlated with fasting plasma TG concentrations[27]. We and others 
have shown ApoB-lipoprotein remnants are positively correlated with plasma TGs in the 
fasted and nonfasted states [27]. Plasma TG reflects TG-rich lipoproteins, including intes-
tinal derived chylomicrons and hepatic very low-density lipoproteins containing apoB48 
and apoB100, respectively. Evidence suggests that persistent elevations in apoB-lipoprotein 
remnants by 1 mmol/L in the nonfasted state are associated with a 2.8-fold risk for ischemic 
heart disease [21, 46]. Although nonfasting lipids and apoB-lipoproteins were not meas-
ured in this study, based on previous reports we can predict that individuals with higher 
fasting apoB48-lipoprotein remnants would also have elevated non-fasting TG and apoB-
lipoprotein remnants in the nonfasted state or in response to a high-fat meal [27, 47].
The pathophysiology of dyslipidemia in PCOS has been attributed to elevated insulin 
and androgens that can independently upregulate lipogenesis [27, 48, 49]. We have previ-
ously shown in a PCOS-prone rodent model that androgens via the androgen receptor in-
crease plasma TGs and apoB-lipoproteins, and intestinal secretion of TGs and apoB48 [48]. 
We have also reported that fasting and nonfasting plasma TGs and apoB48 are positively 
correlated with serum free T concentrations in adolescents with and without PCOS [27]. 
In contrast, in a case–control study in premenopausal women with PCOS no correlation of 
plasma apo-B48, total apo-B, or TGs with T was reported [47]. In the present study, fasting 
plasma apoB-lipoproteins were also found not to be correlated with androgen indices in ad-
olescent girls from the Raine cohort.
We have previously shown in obese adolescents, with and without PCOS, that insulin 
resistance is associated with increased fasting and nonfasting plasma TGs and apoB48 
[27]. In this study, we found no association between apoB-lipoprotein remnants with fasting 
plasma insulin or HOMA-IR. Furthermore, apoB-lipoprotein remnants were not associated 
with markers of adiposity including BMI or waist circumference. This is in contrast to our 
previous findings in adolescents and preadolescent children that have shown fasting and 
nonfasting plasma TGs and apoB48-lipoprotein remnants are associated with markers of 
adiposity, including BMI and waist circumference [27, 37, 45]. The discrepancy between 
studies may be due to greater heterogeneity in body weight, HOMA-IR, and androgen in-
dices in the larger Raine population cohort than the smaller sample sizes in used case–con-
trol studies[27].
In the Raine population, participants with both nonalcoholic fatty liver disease and the 
high-risk metabolic cluster have been shown to have increased arterial stiffness, and >37% 
of those with nonalcoholic fatty liver disease were also diagnosed with PCOS [31, 32]. In this 
study we did not measure subclinical ACVD, such as arterial stiffness or cIMT. However 
our findings do highlight that increased apoB-lipoprotein remnants, in particular apoB48, 
may be an early biomarker for increased risk of developing CVD in adolescents who present 
with a high prevalence of cardiometabolic risk factors. [21]. Recent evidence shows that the 
presence of cardiometabolic risk factors in adolescence persist into adulthood, and this may 
contribute to the increased incidence of CVD observed in women with PCOS [1, 3, 50, 51]. 
Early apoB remnant dyslipidemia may predict increased premature development of CVD 
and increased incidence of ischemic CVD events in women with and without PCOS, con-
sistent with findings in other populations [21]. However, given the cross-sectional design of 
our study we cannot determine the causal role of apoB-lipoprotein dyslipidemia on the long-
term incidence of ischemic CVD events. Therefore, the relationship of atherogenic apoB-
lipoprotein cholesterol-dense remnants with early diagnosis of subclinical ACVD, such as 
increased cIMT, and with long-term outcomes of ischemic CVD events in PCOS remains 
to be determined [1, 3]. We were also unable to account for family history of CVD, hyper-
tension, dyslipidemia, apoE genotype, and type 2 diabetes, or other lifestyle factors such 
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as diet and exercise, which may contribute to cardiometabolic risk factors observed in this 
population.
The translation of our study findings to other studies using different PCOS diagnostic 
criteria will depend on the criteria used. However, we found no difference in primary 
outcomes of cardiometabolic risk factors, and apoB48 and apoB100 plasma concentrations 
between NIH-Rotterdam and AEPCOS PCOS diagnostic criteria. Therefore comparing 
other studies with different criteria to our study may not be a major issue for comparability 
of these outcomes. Furthermore, in the AEPCOS criteria we also used a PCOS diagnosis 
at >2 years post menarche, irregular cycle length of >35 days, and a pelvic ultrasound to 
assess ovarian morphology, consistent with current PCOS criteria in adolescents [3, 52]. 
Current guidelines do recommend that ovarian ultrasound assessment in adolescents is not 
required at <8 years post menarche due to the increased frequency of multifollicular ovaries 
in the normal developing ovary [3, 52]. Therefore, the impact of PCOS diagnostic criteria 
and the relationship to the primary outcome of apoB-lipoprotein remnants lipoproteins may 
be considered minimal when defining PCOS in this population.
In conclusion, elevated plasma apoB48-lipoprotein remnants are highly associated with 
cardiometabolic risk factors in adolescent girls with and without PCOS in the Raine cohort. 
In those with PCOS there is a 2-fold higher prevalence of cardiometabolic risk factors which 
may predispose this population of young women to premature development of atheroscle-
rosis and CVD.
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